Published Date: 15-02-2017
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, Europe DNA Diagnostics Market, published by KBV Research, the Europe DNA Diagnostics Market is expected to grow at a CAGR of 11.2% during 2016 -2022.
The Instruments market dominated the Europe DNA Diagnostics Market in 2015, and would grow at a CAGR of 11.7% during the forecast period. The Reagents market is expected attain a market size of $986.1 million by 2022.
The Clinical confirmation diagnostics market contributed the larger revenue share to the Europe DNA Diagnostics Market in 2015, and would grow at a CAGR of 10.8% during the forecast period. The Oncology market is expected to attain a market size of $1.6 billion by 2022. However, Infectious disease testing market is expected to grow at CAGR of 11.2% during 2016-2022.
The report highlights the adoption of DNA Diagnostics in Europe.Based on the Product Types, the Europe DNA Diagnostics Market is segmented into Instruments, Reagents and Service & software segment. Based on the Application, the market is bifurcated into Oncology, Infectious disease testing, Myogenic disorder diagnosis, Clinical confirmation diagnostics, Prenatal diagnosis, Pre-implantation diagnostics and other segments. Based on the Technology, the market is bifurcated into PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry and other segments. Further, the market is segmented into POC (Point-of-Care), Central Laboratories and Self-Testing segments based on the End Users. The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Europe.
Key Players profiled in the report includes Sysmex Corporation, Bayer Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid Inc, Hologic Corporation, Illumina, Novartis International Ag, Thermo Fisher Scientific Inc. and Bio-Rad Laboratories.
The market is segmented based on Product Types, Application, Technology, End User and Country.